The Effect of Creatine Supplementation Associated With Resistance Training on Sarcopenia Parameters and Muscle Density in Prostate Cancer Patients After Androgen Deprivation Therapy


Condition: Prostate Cancer, Sarcopenia

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT07463092

Sponsor: University of Sao Paulo

Eligibility:

  • Age: minimum 40 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • Men aged ≥ 40 years;
  • Patients with histologically or cytologically confirmed localized prostate cancer;
  • Patients who have undergone surgical castration or pharmacological castration with gonadotropin-releasing hormone (GnRH/LHRH) agonists or antagonists for at least six months prior to the start of the intervention;
  • Patients receiving continuous or intermittent androgen deprivation therapy;
  • Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
  • Not engaged in resistance training in the three months prior to the intervention;
  • Not using creatine supplementation in the three months prior to the intervention;
  • Willing to participate in a 12-week intervention consisting of resistance training performed three times per week and daily supplementation with creatine monohydrate or maltodextrin.

Exclusion Criteria:

  • Patients with insulin-dependent diabetes mellitus;
  • Patients with dialysis-dependent renal failure;
  • Patients with severe chronic liver disease;
  • Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²;
  • Any hormonal treatment outside that established by the medical team;
  • Patients planning to undergo chemotherapy within the next six months.

View trial on ClinicalTrials.gov